Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its news flow, as reflected in recent press releases and SEC filings, centers on clinical trial progress, scientific publications, financing activities and investor outreach related to its pipeline.
Investors following MNMD news can track updates on MM120, MindMed’s proprietary, pharmaceutically optimized form of lysergide D-tartrate (LSD), which the company is developing for generalized anxiety disorder and major depressive disorder. Recent announcements have highlighted Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD and MDD, as well as the publication of a Phase 2b GAD trial in the Journal of the American Medical Association (JAMA). MindMed also issues news on MM402, its proprietary form of R(−)-MDMA being developed for core symptoms of autism spectrum disorder.
MindMed’s news releases frequently cover financial results, underwritten public offerings of common shares, and the intended use of proceeds to fund research and development and general corporate purposes. The company also announces participation in major healthcare and investor conferences, such as events hosted by J.P. Morgan, Stifel, Jefferies, Evercore and Piper Sandler, and provides details on investor webcasts and corporate presentations.
This MNMD news page aggregates these company-issued updates so readers can review clinical milestones, capital markets transactions, and corporate communications in one place. Regularly reviewing this information can help market participants understand how MindMed reports on the advancement of its brain health pipeline and its interactions with the investment community.
MindMed (NASDAQ: MNMD) announced that CEO Rob Barrow will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 2:15 p.m. PT. The company said the presentation will review progress across its late-stage psychiatry programs and outline a "defining year" with three anticipated Phase 3 topline readouts and plans toward potential FDA submissions in GAD and MDD.
A live audio webcast will be available to investors, with a replay posted 24 hours after the webcast and accessible on MindMed’s website for 30 days.
MindMed (NASDAQ: MNMD) granted inducement stock options to two newly hired non-executive employees totaling 31,500 common shares, with an effective grant date of December 15, 2025.
The options carry an exercise price equal to MindMed’s closing share price on the grant date, vest over a four-year schedule (25% after one year, then monthly over three years), and are subject to continued employment. The grants were approved by the Compensation Committee on December 14, 2025 under NASDAQ Rule 5635(c)(4) and were issued outside the company’s existing equity incentive plans as material inducements to employment.
MindMed (NASDAQ: MNMD) announced inducement option grants to four newly hired non‑executive employees totaling 182,100 options with effective grant dates of Nov 17, 2025, Nov 24, 2025 and Dec 1, 2025. The exercise price for each option equals the closing price of MindMed common shares on its respective grant date.
The options vest over four years with 25% vesting after one year and the remaining 75% vesting monthly over the next three years, subject to continued employment. Grants were approved by MindMed’s Compensation Committee on Nov 24, 2025 and were issued outside the company’s equity incentive plans in accordance with NASDAQ Rule 5635(c)(4).
MindMed (NASDAQ: MNMD) reported Q3 2025 results and program updates on November 6, 2025. Cash, cash equivalents and investments were $209.1M as of September 30, 2025; the company completed an underwritten offering on October 31, 2025 with net proceeds of $242.8M, and said combined resources should fund operations into 2028.
Clinical highlights: Phase 2b MM120 GAD results published in JAMA (MM120 100 µg: 65% response, 48% remission at Week 12); MM120 Phase 3 enrollment remains on track with topline readouts expected mid-2026 (Emerge, MDD) and across 1H/2H 2026 for GAD studies (Voyage, Panorama). MM402 Phase 2a in ASD planned for 4Q 2025.
Mind Medicine (NASDAQ: MNMD) announced management will present at four investor conferences in Nov–Dec 2025: Stifel Healthcare on Nov 12, 2025 at 1:20 PM ET (New York), Jefferies Global Healthcare on Nov 18, 2025 at 12:00 PM GMT (London), Evercore Healthcare fireside on Dec 2, 2025 at 12:30 PM ET (Coral Gables), and Piper Sandler fireside on Dec 3, 2025 at 3:00 PM ET (New York).
Each event will offer an audio webcast and replays will be available on MindMed’s Investor Relations website for up to 90 days after each presentation.
MindMed (NASDAQ: MNMD) announced inducement equity grants to three newly hired non‑executive employees, consisting of options to purchase an aggregate of 90,750 common shares with an effective grant date of November 3, 2025.
The options carry an exercise price equal to MindMed’s closing share price on the grant date, vest over four years with 25% vesting on the first anniversary and the remaining 75% vesting in substantially equal monthly installments over the following three years, subject to continued employment.
The awards were approved by the compensation committee on October 31, 2025 as material inducements under NASDAQ Rule 5635(c)(4) and were granted outside MindMed’s equity incentive plans.
Mind Medicine (NASDAQ: MNMD) closed an underwritten public offering of 21,131,250 common shares at $12.25 per share, including the underwriters’ full exercise of an option for an additional 2,756,250 shares.
The gross proceeds were approximately $259 million before underwriting discounts, commissions and offering expenses. The offering closed on October 31, 2025. MindMed intends to use net proceeds to fund research and development, working capital and general corporate purposes, and may use a portion to invest in or acquire complementary businesses or compounds, although it has no current plans or commitments for acquisitions.
Mind Medicine (NASDAQ: MNMD) will report Q3 2025 financial results on Thursday, November 6, 2025 and host a live webcast at 4:30 p.m. EST to discuss results and recent business updates for the quarter ended September 30, 2025.
Listeners can register for the live webcast and analysts can register for the Q&A via the company links. A replay will be available in the Investor Relations section at ir.mindmed.co and archived for at least 30 days. Participants are advised to join 15 minutes before the start time.
Mind Medicine (NASDAQ: MNMD) priced an underwritten public offering of 18,375,000 common shares at $12.25 per share, expected to raise approximately $225 million in gross proceeds. The underwriters have a 30-day option to purchase up to an additional 2,756,250 shares at the offering price.
All shares are being sold by MindMed, with net proceeds intended for research and development of product candidates, and for working capital and general corporate purposes; the company said it may use some proceeds for acquisitions but has no current plans. The offering is expected to close on or about October 31, 2025, subject to customary conditions.
Mind Medicine (NASDAQ: MNMD) announced on October 29, 2025 a proposed underwritten public offering of common shares and, for certain investors, pre-funded warrants to purchase common shares. The offering may include a 30-day underwriter option to buy additional common shares at the public offering price, less discounts and commissions.
MindMed said it intends to use net proceeds for research and development, working capital and general corporate purposes, and may invest in or acquire complementary businesses though it has no current plans or agreements for acquisitions. Securities are being offered under a shelf registration on Form S-3 (File No. 333-280548) that was filed June 28, 2024 and became effective upon filing; final terms will be in a prospectus supplement to be filed with the SEC.